New combo therapy offers hope for head and neck cancer patients unable to take standard chemo
NCT ID NCT05245682
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests the safety of combining the drug tolinapant with radiation therapy for people with head and neck cancer that has spread locally but hasn't been treated yet. Participants are those who cannot receive the standard chemotherapy drug cisplatin. The goal is to see if this combination is safe and feasible, and whether it can kill more cancer cells.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CARCINOMA OF UNKNOWN PRIMARY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New combo therapy targets tough head and neck cancers
- Blood test may outshine scans for spotting hidden cancer after radiation
- Lifting weights, lifting spirits: exercise eases chemo side effects
- New cocktail aims to shrink head and neck tumors before surgery
- New chemo combo shows promise for head and neck cancer before surgery
- New drug duo aims to shrink oral cancers before surgery